AbbVie Inc (ABBV)vsWarby Parker Inc (WRBY)
ABBV
AbbVie Inc
$290.89
+1.71%
HEALTHCARE · Cap: $504.37B
WRBY
Warby Parker Inc
$24.43
-2.55%
HEALTHCARE · Cap: $2.89B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6963% more annual revenue ($64.39B vs $911.61M). ABBV leads profitability with a 9.8% profit margin vs 0.8%. ABBV trades at a lower P/E of 80.6x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
WRBY
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$290.89
$137.92 premium
Margin of Safety
-6.1%
Fair Value
$20.73
Current Price
$24.43
$3.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
ROE of 0.4% — below average capital efficiency
0.8% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : WRBY
WRBY has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : WRBY
The primary concerns for WRBY are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 389.0x leaves little room for execution misses. Thin 0.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
WRBY carries more volatility with a beta of 1.90 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 30/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. (WRBY) is an innovative direct-to-consumer eyewear company that has redefined the eyewear shopping experience since its inception in 2010. With a successful blend of e-commerce and physical retail expansion, the company offers stylish and affordable prescription glasses and sunglasses, appealing to a broad demographic. Warby Parker is distinguished by its commitment to social responsibility, exemplified by its "Buy a Pair, Give a Pair" initiative, which underscores its dedication to making a positive impact. As the company leverages its strong brand reputation and effective marketing strategies, it is well-positioned for continued growth in the increasingly competitive eyewear sector, addressing evolving consumer preferences while enhancing its social mission.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?